Literature DB >> 20188315

Efficacy and costs of nutritional rehabilitation in muscle-wasted patients with chronic obstructive pulmonary disease in a community-based setting: a prespecified subgroup analysis of the INTERCOM trial.

Carel R van Wetering1, Martine Hoogendoorn, Roelinka Broekhuizen, Gonnie J W Geraerts-Keeris, Dirk R A J De Munck, Maureen P M H Rutten-van Mölken, Annemie M W J Schols.   

Abstract

RATIONALE: Limited data are available on effectiveness and costs of nutritional rehabilitation for patients with COPD in community care.
METHODS: In a 2-year RCT, 199 COPD patients (FEV(1)%pred. 60% [SD 16%]) and impaired exercise capacity were randomized to the interdisciplinary community-based COPD management program (INTERCOM) or usual care (UC). A prescheduled subgroup analysis was performed on 39 of 199 patients who were muscle wasted and received UC or nutritional therapy in combination with exercise training. Body composition, muscle strength, and exercise capacity were assessed at baseline and 4, 12, and 24 months.
RESULTS: Between group differences after 4 months in favor of the intervention group: fat free mass index (FFMI 0.9 kg/m(2) [SE = 0.2, P < .001]), body mass index (BMI 1.0 kg/m(2) [SE = 0.4, P = .009]), maximum inspiratory mouth pressure (Pimax 1.4 kPa [SE = 0.5, P = .011]), quadriceps average power (QAP 13.1 Watt [SE=5.8, P = .036]), 6-minute walking distance (6MWD 27 m, [SE = 11.5, P = .028]), cycle endurance time (CET 525 seconds [SE=195, P = .013]), and peak exercise capacity (Wmax 12 Watt [SE = 5, P = .036]). Between group difference over 24 months in favor of the intervention group: Pimax 1.7 kPa (SE = 0.53, P = .004), QAP 19 Watt (SE = 6, P = .005), 6MWD 57 (SE = 19, P = .006), and CET 485 seconds (SE = 159, P = .006). After 4 months total costs were Euro 1501 higher in the intervention group than in the UC group (P < .05), but not significantly different after 24 months. Hospital admission costs were significantly lower in the intervention group -euro 4724 (95% CI -7704, -1734).
CONCLUSION: This study in muscle-wasted COPD patients with moderate airflow obstruction shows a prolonged positive response to nutritional support integrated in a community-based rehabilitation program. (c) 2010 American Medical Directors Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20188315     DOI: 10.1016/j.jamda.2009.12.083

Source DB:  PubMed          Journal:  J Am Med Dir Assoc        ISSN: 1525-8610            Impact factor:   4.669


  25 in total

1.  Anorexia of aging: a true geriatric syndrome.

Authors:  J E Morley
Journal:  J Nutr Health Aging       Date:  2012-05       Impact factor: 4.075

2.  Sarcopenia with limited mobility: an international consensus.

Authors:  John E Morley; Angela Marie Abbatecola; Josep M Argiles; Vickie Baracos; Juergen Bauer; Shalender Bhasin; Tommy Cederholm; Andrew J Stewart Coats; Steven R Cummings; William J Evans; Kenneth Fearon; Luigi Ferrucci; Roger A Fielding; Jack M Guralnik; Tamara B Harris; Akio Inui; Kamyar Kalantar-Zadeh; Bridget-Anne Kirwan; Giovanni Mantovani; Maurizio Muscaritoli; Anne B Newman; Filippo Rossi-Fanelli; Giuseppe M C Rosano; Ronenn Roubenoff; Morris Schambelan; Gerald H Sokol; Thomas W Storer; Bruno Vellas; Stephan von Haehling; Shing-Shing Yeh; Stefan D Anker
Journal:  J Am Med Dir Assoc       Date:  2011-07       Impact factor: 4.669

3.  Editorial: Frailty, Comorbidity, and COPD.

Authors:  E Charbek; J R Espiritu; R Nayak; J E Morley
Journal:  J Nutr Health Aging       Date:  2018       Impact factor: 4.075

Review 4.  Reconsideration of frailty in relation to surgical indication.

Authors:  Kay Maeda; Yoshikatsu Saiki
Journal:  Gen Thorac Cardiovasc Surg       Date:  2017-11-23

Review 5.  An official American Thoracic Society/European Respiratory Society statement: update on limb muscle dysfunction in chronic obstructive pulmonary disease.

Authors:  François Maltais; Marc Decramer; Richard Casaburi; Esther Barreiro; Yan Burelle; Richard Debigaré; P N Richard Dekhuijzen; Frits Franssen; Ghislaine Gayan-Ramirez; Joaquim Gea; Harry R Gosker; Rik Gosselink; Maurice Hayot; Sabah N A Hussain; Wim Janssens; Micheal I Polkey; Josep Roca; Didier Saey; Annemie M W J Schols; Martijn A Spruit; Michael Steiner; Tanja Taivassalo; Thierry Troosters; Ioannis Vogiatzis; Peter D Wagner
Journal:  Am J Respir Crit Care Med       Date:  2014-05-01       Impact factor: 21.405

Review 6.  Long-Term Outcome of Chronic Obstructive Pulmonary Disease: A Review.

Authors:  Yong Suk Jo
Journal:  Tuberc Respir Dis (Seoul)       Date:  2022-07-13

7.  Skeletal Muscle Dysfunction in Chronic Obstructive Pulmonary Disease. What We Know and Can Do for Our Patients.

Authors:  Ariel Jaitovich; Esther Barreiro
Journal:  Am J Respir Crit Care Med       Date:  2018-07-15       Impact factor: 21.405

Review 8.  Understanding the mechanisms and treatment options in cancer cachexia.

Authors:  Kenneth Fearon; Jann Arends; Vickie Baracos
Journal:  Nat Rev Clin Oncol       Date:  2012-12-04       Impact factor: 66.675

9.  Frailty consensus: a call to action.

Authors:  John E Morley; Bruno Vellas; G Abellan van Kan; Stefan D Anker; Juergen M Bauer; Roberto Bernabei; Matteo Cesari; W C Chumlea; Wolfram Doehner; Jonathan Evans; Linda P Fried; Jack M Guralnik; Paul R Katz; Theodore K Malmstrom; Roger J McCarter; Luis M Gutierrez Robledo; Ken Rockwood; Stephan von Haehling; Maurits F Vandewoude; Jeremy Walston
Journal:  J Am Med Dir Assoc       Date:  2013-06       Impact factor: 4.669

10.  Body mass index and prognosis in patients hospitalized with acute exacerbation of chronic obstructive pulmonary disease.

Authors:  Mitja Lainscak; Stephan von Haehling; Wolfram Doehner; Irena Sarc; Tina Jeric; Kristina Ziherl; Mitja Kosnik; Stefan D Anker; Stanislav Suskovic
Journal:  J Cachexia Sarcopenia Muscle       Date:  2011-03-01       Impact factor: 12.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.